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674 Pedersen et alNonmelanoma skin cancer (NMSC) is the most
common cancer in humans, and the incidence is
increasing, particularly among the elderly.1 Exposure
to ultraviolet (UV) light and a UV-susceptible skin
phenotype have been established as important risk
factors for NMSC. In addition, the use of immunosup-
pressants (eg, cyclosporine and azathioprine) inducesCAPSULE SUMMARY
d Hydrochlorothiazide is photosensitizing
and has been linked to lip cancer.
d We found a dose-dependent increased
risk of nonmelanoma skin cancer,
particularly squamous cell carcinoma,
among users of hydrochlorothiazide.
d Hydrochlorothiazide use should be
carefully considered because of its
association with nonmelanoma skin
cancer.NMSC, and other drugs have
been suggested to either in-
crease (eg, topical and sys-
temic calcineurin inhibitors)
or decrease (eg, aspirin and
other nonsteroidal anti-
inflammatory drugs) the risk
of NMSC.2-5
Recently, we reported a
strong association between
use of the diuretic hydrochlo-
rothiazide (HCTZ) and squa-
mous cell carcinoma (SCC) of
the lip.6 We found a clear
dose-response pattern, with
an estimated 7-fold increased
risk of SCC lip cancer with cumulative use of
100,000 mg or more of HCTZ. Our findings were in
line with the results of previous studies from the
United States7 and the recent classification of HCTZ as
possibly carcinogenic to humans (group 2B) by the
International Agency for Research on Cancer.8 As
HCTZ is among the most widely used drugs in the
United States and Western Europe,9 a carcinogenic
effect of HCTZ would have a considerable impact on
public health.
Few studies have investigated the association be-
tween thiazide use and NMSC risk.10-13 Although the
study results have been inconsistent, they indicate
that HCTZuse increases the risk of NMSC. Someof the
inconsistencies may derive from difficulties in disen-
tangling the effect of HCTZ from that of other
antihypertensives, as HCTZ is mainly prescribed in
combination with other diuretics (primarily amilor-
ide) or nondiuretic antihypertensives.10-13 Therefore,
we were interested in examining the association
between HCTZ use and NMSC risk more extensively
and evaluating the individual effect of HCTZ.6
Specifically, we used detailed data from the Danish
demographic, prescription, and disease registries to
examine the association between HCTZ use and the
risk of basal cell carcinoma (BCC) or SCC of the skin.
METHODS
We performed a nested case-control analysis
based on nationwide registry data. We compared
HCTZ use among persons in whom SCC and BCC of
the skin had been diagnosed with that of cancer-freepopulation controls and estimated odds ratios (ORs)
for SCC and BCC associatedwith previous HCTZ use.
Data sources
We obtained data from 5 nationwide data sources:
the Danish Cancer Registry,14 the National
Prescription Registry,15 the National PatientRegistry,16 the Danish
Education Registers,17 and
the Danish Civil Registration
System.18 We linked all data
sources using the unique
civil registration number as-
signed to all Danish resi-
dents. Details of codes used
to define drug exposure and
covariates have been pro-
vided elsewhere.6
Selection of patients with
NMSC
The patients with NMSC
were Danish residents withhistologic verification of their first diagnosis of SCC
or BCC of the skin between January 1, 2004, and
December 31, 2012. We excluded patients with SCC
of the lip, as they were evaluated in our previous
study.6 We required patients to have no previous
skin or other cancer diagnoses before the first
diagnosis of BCC or SCC (index date) and to have
resided in Denmark for at least 10 consecutive years
before the index date. We also required patients to
have no record of organ transplantation; HIV diag-
nosis; or use of azathioprine, cyclosporine, or
mycophenolate mofetil, as immunosuppressive dis-
ease and therapy may predispose to skin cancer.2,19
We defined the date of the first skin cancer diagnosis
as the index date.
Population controls
Controls were selected by risk-set sampling. For
each case, wematched 20 population controls by sex
and birth year, applying the same selection criteria as
for cases. Controls were allotted the index dates of
their corresponding cases. As individuals were
eligible to be controls before they became case
patients, the calculated ORs provide unbiased esti-
mates of the incidence rate ratios that would have
emerged from a cohort study based on the source
population.
Definition of exposure
On the basis of prescription data from
1995 onward, ever use of HCTZ was defined as
having filled 1 or more prescriptions for an
Abbreviations used:
BCC: basal cell carcinoma
CI: confidence interval
HCTZ: hydrochlorothiazide
NMSC: nonmelanoma skin cancer
OR: odds ratio
SCC: squamous cell carcinoma
UV: ultraviolet
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never use as no HCTZ-containing prescription. In
Denmark, HCTZ is prescribed almost exclusively as a
part of combination preparations with potassium-
sparing diuretic amiloride or nondiuretic antihyper-
tensives, predominantly angiotensin-converting
enzyme inhibitors or angiotensin II receptor antag-
onists. The content of HCTZ was identified in all
combination or single drugs dispensed to individuals
in the study population, and on the basis of this
information the cumulative dose of HCTZ to which
each individual had been exposed up to index date
was calculated. High use of HCTZ was defined as
filled prescriptions equivalent to 50,000 mg or more
of HCTZ, corresponding to 2000 or more defined
daily doses (ie, ;6 years of cumulative use).
Prescriptions filled within 2 years before the index
date (lag time) were disregarded, primarily to allow a
reasonable induction period for an effect on BCC or
SCC risk and to guard against the possibility that
medical attention before the skin cancer diagnosis
had influenced the decision to prescribe HCTZ.20
Other variables
We defined potential confounders on the basis of
the following data: (1) use of selected drugs with
suggested photosensitizing properties, including
oral retinoids, topical retinoids, tetracycline, macro-
lides, aminoquinolines, amiodarone, and methox-
ypsoralene10,13,21,22; (2) use of drugs with suggested
antineoplastic effects, including aspirin, nonsteroidal
anti-inflammatory drugs, and statins3; (3) composite
measures of hospital diagnoses and disease-specific
drugs defining medical histories of diabetes, chronic
obstructive pulmonary disease, chronic renal insuf-
ficiency, or conditions associated with heavy alcohol
consumption (see the Supplemental and Sensitivity
Analyses; available at http://www.jaad.org); (4)
Charlson comorbidity index scores (0, low; 1-2,
medium; or $3, high) derived from the prevalence
of 19 chronic conditions; and (5) highest achieved
education (basic, medium, higher, or unknown).
Exposure to each potential confounder drug was
defined as 2 or more prescriptions on separate dates,
and the hospital history of each of the selectedmedical conditions was defined as a primary or
secondary discharge or outpatient diagnosis. For all
covariates, we disregarded information within
2 years before the index date.
Analyses
All analyses followed a conventional matched
case-control approach. We computed the frequency
and proportion of cases and controls within cate-
gories of the exposure and covariates. We used
conditional logistic regression analysis to compute
ORs with 95% confidence intervals (CIs) for the
association of BCC or SCC with HCTZ use adjusted
for the predefined potential confounders. In addi-
tion, to examine potential dose-response relation-
ships, we stratified analyses according to predefined
categories of cumulative HCTZ use. The statistical
significance of the dose-response pattern was as-
sessed by restriction to HCTZ ever users and
estimation of the incremental OR for each
10,000 mg of HCTZ by using ordinary logistic
regression while also adjusting for sex and age as a
continuous variable. In all analyses, BCC and SCC
were analyzed separately, and those with never use
of HCTZ served as the reference group unless stated
otherwise. We performed a number of preplanned
supplementary analyses, as outlined in the
Supplemental and Sensitivity Analyses.
Ethical approval
The Danish Data Protection Agency and Statistics
Denmark’s Scientific Board approved the study.
According to Danish law, ethical approval is not
required for registry-based studies.
Software
All analyses were performed using STATA Release
14.1 (StataCorp, College Station, TX).
RESULTS
The study population comprised 71,533 case
patients with BCC and 8629 case patients with SCC
(Fig 1) who were matched with 1,430,883 and
172,462 population controls, respectively. Baseline
characteristics were generally similar between case
patients and controls, except that the BCC case
patients were slightly better educated than the
controls (Table I).
Overall, 2.7% of the BCC case patients and 2.1% of
the controls were high users ($50,000 mg) of HCTZ,
yielding an adjusted OR of 1.29 (95% CI, 1.23-1.35)
for BCC. The corresponding OR for SCC was 3.98
(95% CI, 3.68-4.31) based on high use of HCTZ in
10.0% of case patients and 2.8% of controls. Clear
dose-response relationships were observed with
Fig 1. Flowchart of case selection. *Azathioprine, cyclo-
sporine, and mycophenolate mofetil. BCC, Basal cell
carcinoma; NMSC, nonmelanoma skin cancer; SCC, squa-
mous cell carcinoma.
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ORs observed in the upper exposure category
($200,000 mg) (BCC: OR, 1.54; 95% CI, 1.38-1.71,
test for trend P\ .001; SCC: OR, 7.38; 95% CI, 6.32-
8.60, test for trend P\.001 [Table II and Fig 2]). The
proportion of skin cancers attributable to HCTZ use
(ie, attributable proportion, see Methods) was 0.6%
for BCC and 9.0% for SCC.
Little variation was seen in the association be-
tween HCTZ use and BCC or SCC risk in the
subgroup analyses, except for notably stronger
associations among younger individuals and females
(Table II). In analyses stratified according to tumor
localization, we observed stronger associations for
cancers at sun-exposed skin sites, especially the skin
of the lower limbs (Table III).
We found no associations for BCC or SCC risk with
use of other diuretics and other hypertensives,
including bendroflumethiazide, calcium channel
blockers, angiotensin-converting enzyme inhibitors,
angiotensin II receptor antagonists, furosemide,
indapamide, or nifedipine, neither overall or accord-
ing to the cumulative use of the individual drugs (see
Supplemental Tables I-VII in the Supplemental and
Sensitivity Analyses).
In analyses excluding ever use of amiloride, HCTZ
use exhibited dose to response relationships with the
risk of BCC or SCC similar to those in the main
analysis (Supplemental Table VIII in the
Supplemental and Sensitivity Analyses), though
small numbers precluded analyses of cumulative
HCTZ use in excess of 100,000 mg.
DISCUSSION
In this large nationwide study including more
than 70,000 patients with BCC and 8000 patients with
SCC, we found a substantially increased risk of
NMSC, particularly SCC, associated with HCTZ use.
We observed clear dose-response patterns for both
BCC and SCC, with a more than a 7-fold increased
risk of SCC for a cumulative use of 200,000 mg or
more of HCTZ. In addition, for both BCC and SCC,
the associations with HCTZ use became stronger
with increasing lag time before diagnoses. Assuming
causality, the present results suggest that 1 of 11 SCC
cases diagnosed during the study period can be
attributed to HCTZ use. The increased risk of BCC
and SCC appeared to be specific for HCTZ use
among a range of examined drugs with similar
indications.
The main strengths of our study include
the population-based design and large sample
Table I. Characteristics of BCC and SCC cases and matched controls
Characteristic
BCC SCC
Case patients
(n = 71,553)
Controls
(n = 1,430,883)
Case patients
(n = 8629)
Controls
(n = 172,462)
Age, median (IQR) 66 (57-76) 66 (57-76) 77 (68-85) 77 (68-85)
Male sex 33,817 (47.3%) 676,286 (47.3%) 4803 (55.7%) 96,020 (55.7%)
Use of HCTZ
Never use 63,653 (89.0%) 1,281,894 (89.6%) 6817 (79.0%) 149,944 (86.9%)
Ever use 7900 (11.0%) 148,989 (10.4%) 1812 (21.0%) 22,518 (13.1%)
High use 1897 (2.7%) 30,075 (2.1%) 862 (10.0%) 4802 (2.8%)
Use of photosensitizing drugs
Topical retinoids 197 (0.3%) 2279 (0.2%) 25 (0.3%) 168 (0.1%)
Oral retinoids 465 (0.6%) 5671 (0.4%) 46 (0.5%) 379 (0.2%)
Tetracycline 1563 (2.2%) 23,299 (1.6%) 170 (2.0%) 2310 (1.3%)
Macrolides 16,515 (23.1%) 295,632 (20.7%) 1860 (21.6%) 32,524 (18.9%)
Aminoquinolines 4405 (6.2%) 70,195 (4.9%) 605 (7.0%) 9324 (5.4%)
Amiodarone 370 (0.5%) 6106 (0.4%) 64 (0.7%) 1136 (0.7%)
Methoxypsoralene 50 (0.1%) 859 (0.1%) 13 (0.2%) 93 (0.1%)
Other drug use
Aspirin 14,146 (19.8%) 284,771 (19.9%) 2955 (34.2%) 54,337 (31.5%)
Nonaspirin NSAID 37,353 (52.2%) 726,091 (50.7%) 4727 (54.8%) 89,452 (51.9%)
Statins 11,451 (16.0%) 226,657 (15.8%) 1779 (20.6%) 32,413 (18.8%)
Glucocorticoids 9057 (12.7%) 168,808 (11.8%) 1452 (16.8%) 24,456 (14.2%)
Diagnoses
Alcohol-associated conditions 1881 (2.6%) 49,294 (3.4%) 221 (2.6%) 4491 (2.6%)
Diabetes 3884 (5.4%) 97,388 (6.8%) 783 (9.1%) 14,567 (8.4%)
COPD 3093 (4.3%) 66,770 (4.7%) 642 (7.4%) 10,947 (6.3%)
Chronic renal insufficiency 581 (0.8%) 12,031 (0.8%) 164 (1.9%) 2,114 (1.2%)
CCI score
0 52,827 (73.8%) 1,045,348 (73.1%) 5132 (59.5%) 109,776 (63.7%)
1 11,454 (16.0%) 235,072 (16.4%) 1913 (22.2%) 36,079 (20.9%)
2 4132 (5.8%) 83,546 (5.8%) 827 (9.6%) 14,534 (8.4%)
$3 3140 (4.4%) 66,917 (4.7%) 757 (8.8%) 12,073 (7.0%)
Education
Short, 7-10 y 21,039 (29.4%) 523,901 (36.6%) 3252 (37.7%) 68,072 (39.5%)
Medium, 11-12 y 27,583 (38.5%) 509,694 (35.6%) 2619 (30.4%) 49,864 (28.9%)
Long, $13 y 18,265 (25.5%) 282,520 (19.7%) 1322 (15.3%) 24,771 (14.4%)
Unknown 4666 (6.5%) 114,768 (8.0%) 1436 (16.6%) 29,755 (17.3%)
Data are presented as n (%) unless otherwise noted.
BCC, Basal cell carcinoma; CCI, Charlson comorbidity index; COPD, chronic obstructive pulmonary disease; HCTZ, hydrochlorothiazide; IQR,
interquartile range; NSAID, nonsteroidal anti-inflammatory drug; SCC, squamous cell carcinoma.
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including prescription data, medical conditions,
and skin or other cancer diagnoses. Use of the
Prescription Registry yielded complete and
detailed long-term information on use of HCTZ
or other drugs during an exposure period of up to
18 years.15 Cancer diagnoses obtained from the
Cancer Registry were restricted to histologically
verified cases, further enhancing validity.14
This study also had some limitations. Most impor-
tantly, we did not have information on 2 major risk
factors for BCC and SCC, namely, UV exposure and
skin phenotype. However, we find it unlikely that
sun habits would be markedly different betweenusers and nonusers of HCTZ. We had no information
on ethnicity or skin type; however, the majority of
Danes are of white origin. Still, information on UV
exposure and skin phenotype would have been
useful in evaluating photosensitivity as the explan-
atory mechanism for an increased skin cancer risk
with HCTZ use.
Severe skin photosensitivity reactions to HCTZ use
have been reported.23,24 In a recent survey of US
dermatologists, patients with multiple SCC tumors
reported a frequent history of HCTZ use.25 However,
only a few observational studies have investigated the
association between HCTZ use and NMSC risk.10-13
A Dutch study reported no association between
Fig 2. Dose-response pattern between cumulative hydrochlorothiazide dose and risk of basal
cell carcinoma (A) and squamous cell carcinoma (B). Error bars represent 95% confidence
intervals.
Table II. Association between exposure to hydrochlorothiazide and risk of NMSC according to cumulative
hydrochlorothiazide use
Subgroup Case patients Controls Adjusted OR (95% CI)* Adjusted OR (95% CI)y
Basal cell carcinoma
Nonuse 63,653 1,281,894 1.0 (ref) 1.0 (ref)
Ever use 7900 148,989 1.07 (1.04-1.10) 1.08 (1.05-1.10)
High use ($50,000 mg) 1897 30,075 1.28 (1.22-1.34) 1.29 (1.23-1.35)
Cumulative amount
1-9999 mg 2907 57,782 1.02 (0.98-1.06) 1.02 (0.98-1.06)
10,000-24,999 mg 1815 36,003 1.02 (0.97-1.07) 1.03 (0.98-1.08)
25,000-49,999 mg 1281 25,129 1.03 (0.97-1.09) 1.03 (0.97-1.09)
50,000-74,999 mg 511 9148 1.13 (1.03-1.24) 1.14 (1.04-1.25)
75,000-99,999 mg 271 4700 1.17 (1.03-1.32) 1.18 (1.04-1.33)
100,000-149,999 mg 395 6134 1.29 (1.17-1.43) 1.30 (1.17-1.44)
150,000-199,999 mg 329 4863 1.38 (1.23-1.54) 1.39 (1.24-1.56)
$200,000 mg 391 5230 1.50 (1.35-1.67) 1.54 (1.38-1.71)
Squamous cell carcinoma
Nonuse 6817 149,944 1.0 (ref) 1.0 (ref)
Ever use 1812 22,518 1.80 (1.70-1.90) 1.75 (1.66-1.85)
High use 862 4802 4.05 (3.75-4.39) 3.98 (3.68-4.31)
Cumulative amount
1-9999 mg 392 8369 1.04 (0.93-1.15) 1.01 (0.91-1.12)
10,000-24,999 mg 283 5476 1.14 (1.01-1.29) 1.12 (0.99-1.27)
25,000-49,999 mg 275 3871 1.57 (1.38-1.78) 1.54 (1.36-1.75)
50,000-74,999 mg 133 1432 2.08 (1.74-2.50) 2.05 (1.70-2.46)
75,000-99,999 mg 95 746 2.89 (2.32-3.60) 2.84 (2.28-3.54)
100,000-149,999 mg 180 1104 3.65 (3.10-4.30) 3.56 (3.02-4.20)
150,000-199,999 mg 206 768 5.87 (5.00-6.89) 5.82 (4.96-6.84)
$200,000 mg 248 752 7.53 (6.46-8.77) 7.38 (6.32-8.60)
CI, Confidence interval; NMSC, nonmelanoma skin cancer; OR, odds ratio.
*Adjusted for age, sex, and calendar time by risk-set matching and the conditional analysis.
yFully adjusted model, that is, additionally adjusted for (1) use of topical retinoids, oral retinoids, tetracycline, macrolides, aminoquinolines,
amiodarone, and methoxypsoralene; (2) aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, or statins; (3) history of heavy alcohol
consumption, diabetes, chronic renal insufficiency, or chronic obstructive pulmonary disease; (4) Charlson comorbidity index score (0, low; 2,
medium; or $3, high); and (5) highest achieved education (short, medium, long, or unknown).
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risk,11 whereas a US study found that the use of
diuretics overall was significantly associated with an
increased risk of BCC.26 The apparent discrepancy in
the results of some previous studies and our findingsare likely attributable to differences in exposure
definition (HCTZ vs all thiazides) and outcomes
(SCC vs BCC or NMSC only). A recent study from
the United States found a relation between thiazide
use and risk of SCC, but it did not present results for
Table III. Associations between high use of hydrochlorothiazide ($50,000 mg) and risk of NMSC according to
patient subgroups
Subgroup
Case patients
exposed/unexposed
Controls
exposed/unexposed
Adjusted OR
(95% CI)*
Adjusted OR
(95% CI)y
Basal cell carcinoma
\50 y 20/9584 215/191,556 1.84 (1.16-2.91) 1.91 (1.20-3.03)
50-60 y 156/13,130 2431/263,283 1.29 (1.10-1.52) 1.38 (1.17-1.62)
60-75 y 854/26,068 13,403/522,436 1.27 (1.18-1.36) 1.29 (1.20-1.38)
$75 y 867/14,871 14,026/304,619 1.27 (1.18-1.37) 1.26 (1.17-1.35)
Male 580/30,407 9308/612,587 1.26 (1.15-1.37) 1.26 (1.15-1.37)
Female 1317/33,246 20,767/669,307 1.28 (1.21-1.36) 1.31 (1.23-1.38)
Skin of head and neck 783/24,830 12,996/501,337 1.23 (1.14-1.32) 1.22 (1.13-1.31)
Skin of trunk 274/13,237 4815/264,068 1.12 (0.99-1.27) 1.19 (1.05-1.35)
Skin of upper limb 96/3003 1408/60,577 1.38 (1.11-1.70) 1.41 (1.14-1.75)
Skin of lower limb 114/2496 1513/50,153 1.51 (1.24-1.84) 1.55 (1.27-1.89)
Unspecified part of skin 630/20,087 9343/405,759 1.37 (1.26-1.49) 1.39 (1.27-1.51)
No use of photosensitizing drugs 1259/46,042 20,574/971,208 1.31 (1.23-1.39) 1.34 (1.26-1.43)
CCI score of 0 1103/48,163 17,284/957,511 1.29 (1.21-1.37) 1.28 (1.20-1.37)
No diabetes 1590/60,854 24,502/1,208,817 1.30 (1.23-1.37) 1.28 (1.21-1.35)
No psoriasis or atopic dermatitis 1841/61,975 29,299/1,253,574 1.27 (1.21-1.34) 1.29 (1.23-1.36)
No actinic keratosis 1881/63,512 29,998/1,281,028 1.27 (1.21-1.33) 1.29 (1.22-1.35)
Squamous cell carcinoma
\50 y 7/258 (n\ 5) 61.97 (12.81-299.74) 42.85 (8.31-220.84)
50-60 y 44/581 123/12,595 7.86 (5.48-11.28) 7.61 (5.24-11.04)
60-75 y 282/2429 1327/53,331 4.76 (4.15-5.47) 4.72 (4.10-5.44)
$75 y 529/3549 3349/78,713 3.55 (3.21-3.92) 3.48 (3.15-3.85)
Male 281/3958 1844/84,936 3.32 (2.91-3.79) 3.26 (2.85-3.72)
Female 581/2859 2958/65,008 4.58 (4.15-5.05) 4.46 (4.04-4.94)
Skin of head and neck 292/2964 2188/64,025 2.92 (2.56-3.33) 2.83 (2.48-3.23)
Skin of trunk 46/632 345/13,429 2.93 (2.12-4.06) 2.95 (2.11-4.12)
Skin of upper limb 112/796 541/17,426 4.70 (3.76-5.87) 4.90 (3.90-6.16)
Skin of lower limb 101/482 422/11,115 5.80 (4.54-7.41) 5.88 (4.57-7.56)
Unspecified part of skin 311/1943 1306/43,949 5.57 (4.86-6.38) 5.42 (4.72-6.23)
No use of photosensitizing drugs 567/5053 3380/115,858 3.99 (3.62-4.41) 3.96 (3.59-4.38)
CCI score of 0 464/4223 2618/97,620 4.29 (3.83-4.81) 4.19 (3.74-4.70)
No diabetes 727/6338 3948/138,972 4.13 (3.79-4.50) 4.02 (3.68-4.38)
No psoriasis or atopic dermatitis 823/6608 4679/146,952 4.00 (3.69-4.33) 3.94 (3.63-4.27)
No actinic keratosis 839/6762 4791/149,785 3.98 (3.68-4.31) 3.92 (3.62-4.25)
CCI, Charlson comorbidity index; CI, confidence interval; NMSC, nonmelanoma skin cancer; OR, odds ratio.
*Adjusted for age, sex, and calendar time by risk-set matching and the conditional analysis.
yFully adjusted model, that is, additionally adjusted for (1) use of topical retinoids, oral retinoids, tetracycline, macrolides, aminoquinolines,
amiodarone, and methoxypsoralene; (2) aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, or statins; (3) history of heavy alcohol
consumption, diabetes, chronic renal insufficiency, or chronic obstructive pulmonary disease; (4) Charlson comorbidity index score (0, low; 2,
medium; or $3, high); and (5) highest achieved education (short, medium, long, or unknown).
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ported results specifically for HCTZ. A Danish study
observed an increased risk of SCC, but not BCC, with
the use of HCTZ alone and in combination with
amiloride. However, this study had a limited exposure
period and relatively small sample size based on only
1 of 5 Danish regions, thus precluding detailed
analyses of cumulative HCTZ use.12 A more recent
study from the same region also noted an increased
risk of SCC associated with using the combination of
HCTZ and amiloride. However, the association wasnot further explored and no dose-response analyses
were presented.10
SCC was more strongly associated with HCTZ
use than was BCC, which is in line with the
evidence that cumulative UV exposure plays a
larger role in the etiology of SCC than of BCC.1
Furthermore, the observed associations varied ac-
cording to body site and were stronger for the
limbs than for the trunk, which is compatible with
the notion that the increased NMSC risk associated
with HCTZ use is mediated through a
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tions according to sex may be related to differ-
ences in skin thickness (ie, women have a thinner
layer of both epidermis and dermis than men)28
and sun habits (ie, women are more frequent
tanners than men),29 which may confer a differ-
ence in susceptibility to the effects of photosensi-
tizing exposure.
The associations with HCTZ use also varied
according to age, with the highest ORs for both
BCC (1.91) and SCC (42.85) observed among
persons younger than 50 years. The stronger
association among the youngest subjects
strengthens the argument for a photosensitizing
effect. The decrease in ORs (ie, a measure of
relative risk) with increasing age may also reflect
that NMSC risk increases with age for other reasons
(eg, accumulation of DNA breaks and
immunosenescence).
Lastly (and in line with our previous study), we
found no association between the use of other
antihypertensive drugs and NMSC risk.6 In addition
to the strength of the observed associations, the
specificity of HCTZ use with increased risk of BCC
and SCC supports the potential causal association
between HCTZ use and NMSC risk.
In conclusion, given the considerable use of
HCTZ worldwide and the morbidity associated
with NMSC, a causal association between HCTZ
use and NMSC risk would have significant public
health implications. The use of HCTZ should be
carefully considered, as several other antihyperten-
sive agents with similar indications and efficiency are
available, but without known associations with skin
cancer.
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ANALYSES
First, we repeated the main analyses for other
diuretic drugs with suggested photosensitizing
properties, including bendroflumethiazide and
furosemide.10,12,13 Next, we performed analyses
for other antihypertensives, including angiotensin-
converting enzyme inhibitors, angiotesin II recep-
tor blockers, and calcium channel blockers. In the
analyses of other diuretics and nondiuretic antihy-
pertensives, associations were adjusted for hydro-
chlorothiazide (HCTZ) use. In addition, we
excluded ever-users of amiloride from the main
analyses to obtain risk estimates for basal cell
carcinoma (BCC) and squamous cell carcinoma(SCC) with HCTZ use exclusive of amiloride (pri-
marily preparations of HCTZ and angiotensin-
converting enzyme inhibitors or angiotesin II re-
ceptor blockers). On the basis of the results from
the categoric dose-response analyses, the attribut-
able proportion of HCTZ use for BCC and SCC
(assuming causality) was estimated by adding the
single steps in the dose-response analysis together
(estimated as attributable proportion = (odds ratio 
1)/odds ratio). Finally, we examined associations
between HCTZ use and BCC or SCC risk according
to tumor localization, categorized as skin of the head
and neck, skin of the trunk, skin of the upper limb,
skin of the lower limb, and unspecified part of the
skin.
Supplemental Table I. Association between exposure to bendroflumethiazide and risk of NMSC
Subgroup Cases Controls Adjusted OR (95% CI)* Adjusted OR (95% CI)y
Basal cell carcinoma
Nonuse 53,800 1,081,784 1.0 (ref) 1.0 (ref)
Ever use 17,753 349,099 1.03 (1.01-1.04) 1.03 (1.01-1.05)
High use ($50,000 mg) 4207 81,884 1.03 (1.00-1.07) 1.06 (1.02-1.09)
Cumulative amount
1-999 mg 7130 138,711 1.04 (1.01-1.06) 1.04 (1.01-1.07)
1000-2499 mg 3384 67,970 1.00 (0.97-1.04) 1.02 (0.98-1.06)
2500-4999 mg 3032 60,534 1.01 (0.97-1.05) 1.02 (0.98-1.06)
5000-7499 mg 1770 33,840 1.06 (1.00-1.11) 1.08 (1.02-1.13)
7500-9999 mg 1078 20,815 1.04 (0.98-1.11) 1.07 (1.00-1.14)
$10,000 mg 1359 27,229 1.00 (0.95-1.06) 1.03 (0.97-1.09)
Squamous cell carcinoma
Nonuse 5717 115,881 1.0 (ref) 1.0 (ref)
Ever use 2912 56,581 1.05 (1.00-1.10) 1.02 (0.97-1.08)
High use 691 14,669 0.93 (0.86-1.02) 0.98 (0.90-1.07)
Cumulative amount
1-999 mg 1165 20,507 1.14 (1.07-1.22) 1.09 (1.01-1.16)
1000-2499 mg 560 11,079 1.01 (0.92-1.11) 0.99 (0.90-1.09)
2500-4999 mg 496 10,326 0.96 (0.87-1.06) 0.97 (0.88-1.07)
5000-7499 mg 313 5962 1.04 (0.92-1.17) 1.06 (0.94-1.20)
7500-9999 mg 166 3786 0.86 (0.73-1.01) 0.92 (0.78-1.09)
$10,000 mg 212 4921 0.84 (0.73-0.97) 0.92 (0.79-1.06)
CI, Confidence interval; NMSC, nonmelanoma skin cancer; OR, odds ratio; ref, reference.
*Adjusted for age, sex, and calendar time by risk-set matching and the conditional analysis.
yFully adjusted model, that is, additionally adjusted for (1) use of topical retinoids, oral retinoids, tetracycline, macrolides, aminoquinolines,
amiodarone, and methoxypsoralene; (2) aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, or statins; (3) history of heavy alcohol
consumption, diabetes, chronic renal insufficiency, or chronic obstructive pulmonary disease; (4) Charlson comorbidity index score (0, low; 2,
medium; or $3, high); and (5) highest achieved education (short, medium, long, or unknown).
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Supplemental Table II. Association between exposure to furosemide and risk of NMSC
Subgroup Cases Controls Adjusted OR (95% CI)* Adjusted OR (95% CI)y
Basal cell carcinoma
Nonuse 63,951 1,270,426 1.0 (ref) 1.0 (ref)
Ever use 7602 160,457 0.94 (0.91-0.96) 0.94 (0.92-0.97)
High use ($2000 DDD) 1984 43,784 0.90 (0.86-0.94) 0.93 (0.89-0.98)
Cumulative dose (DDD)
1-399 3527 71,788 0.97 (0.94-1.01) 0.97 (0.93-1.00)
400-999 1107 24,040 0.92 (0.86-0.98) 0.93 (0.88-0.99)
1000-1999 984 20,844 0.94 (0.88-1.00) 0.96 (0.90-1.03)
2000-2999 572 12,792 0.89 (0.81-0.96) 0.91 (0.84-1.00)
3000-3999 430 9119 0.93 (0.85-1.03) 0.97 (0.87-1.07)
$4000 982 21,873 0.90 (0.84-0.96) 0.94 (0.88-1.01)
Squamous cell carcinoma
Nonuse 6799 141,645 1.0 (ref) 1.0 (ref)
Ever use 1830 30,817 1.26 (1.19-1.33) 1.11 (1.05-1.18)
High use ($2000 DDD) 611 9609 1.34 (1.23-1.46) 1.18 (1.07-1.30)
Cumulative amount
1-399 715 12,038 1.25 (1.15-1.35) 1.11 (1.02-1.21)
400-999 250 4695 1.11 (0.97-1.26) 0.98 (0.86-1.13)
1000-1999 254 4475 1.20 (1.05-1.37) 1.07 (0.93-1.23)
2000-2999 169 2858 1.25 (1.07-1.47) 1.10 (0.93-1.30)
3000-3999 127 1862 1.42 (1.18-1.71) 1.26 (1.04-1.52)
$4000 315 4889 1.36 (1.20-1.53) 1.23 (1.08-1.40)
CI, Confidence interval; DDD, defined daily dose; NMSC, nonmelanoma skin cancer; OR, odds ratio; ref, reference.
*Adjusted for age, sex, and calendar time by risk-set matching and the conditional analysis.
yFully adjusted model, that is, additionally adjusted for (1) use of topical retinoids, oral retinoids, tetracycline, macrolides, aminoquinolines,
amiodarone, and methoxypsoralene; (2) aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, or statins; (3) history of heavy alcohol
consumption, diabetes, chronic renal insufficiency, or chronic obstructive pulmonary disease; (4) Charlson comorbidity index score (0: low; 2:
medium; or $3: high); and (5) highest achieved education (short, medium, long, or unknown).
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Supplemental Table III. Association between exposure to calcium channel blockers and risk of NMSC
Subgroup Cases Controls Adjusted OR (95% CI)* Adjusted OR (95% CI)y
Basal cell carcinoma
Nonuse 60,645 1,222,633 1.0 (ref) 1.0 (ref)
Ever use 10,908 208,250 1.06 (1.04-1.08) 1.07 (1.04-1.09)
High use ($2000 DDD) 3630 66,445 1.11 (1.07-1.15) 1.13 (1.09-1.17)
Cumulative dose (DDD)
1-399 3321 64,908 1.04 (1.00-1.08) 1.04 (1.00-1.08)
400-999 2078 39,428 1.06 (1.02-1.11) 1.07 (1.02-1.12)
1000-1999 1879 37,468 1.02 (0.97-1.07) 1.03 (0.98-1.08)
2000-2999 1223 23,378 1.07 (1.01-1.13) 1.08 (1.02-1.15)
3000-3999 858 15,491 1.14 (1.06-1.22) 1.16 (1.08-1.24)
$4000 1549 27,576 1.14 (1.08-1.20) 1.16 (1.10-1.22)
Squamous cell carcinoma
Nonuse 6780 138,113 1.0 (ref) 1.0 (ref)
Ever use 1849 34,349 1.10 (1.04-1.16) 0.98 (0.93-1.04)
High use ($2000 DDD) 627 11,514 1.12 (1.03-1.22) 0.98 (0.90-1.08)
Cumulative dose (DDD)
1-399 548 10,382 1.08 (0.99-1.18) 0.97 (0.88-1.07)
400-999 356 6311 1.15 (1.03-1.29) 1.05 (0.94-1.18)
1000-1999 318 6142 1.05 (0.93-1.18) 0.93 (0.83-1.05)
2000-2999 218 4006 1.11 (0.96-1.27) 0.97 (0.84-1.12)
3000-3999 143 2770 1.05 (0.88-1.25) 0.93 (0.78-1.11)
$4000 266 4738 1.16 (1.02-1.32) 1.03 (0.90-1.17)
CI, Confidence interval; DDD, defined daily dose; NMSC, nonmelanoma skin cancer; OR, odds ratio; ref, reference.
*Adjusted for age, sex, and calendar time by risk-set matching and the conditional analysis.
yFully adjusted model, that is, additionally adjusted for (1) use of topical retinoids, oral retinoids, tetracycline, macrolides, aminoquinolines,
amiodarone, and methoxypsoralene; (2) aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, or statins; (3) history of heavy alcohol
consumption, diabetes, chronic renal insufficiency, or chronic obstructive pulmonary disease; (4) Charlson comorbidity index score (0, low; 2,
medium; or $3, high); and (5) highest achieved education (short, medium, long, or unknown).
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Supplemental Table IV. Association between exposure to ACE inhibitors and risk of NMSC
Subgroup Cases Controls Adjusted OR (95% CI)* Adjusted OR (95% CI)y
Basal cell carcinoma
Nonuse 58,669 1,167,222 1.0 (ref) 1.0 (ref)
Ever use 12,884 263,661 0.97 (0.95-0.99) 0.98 (0.96-1.00)
High use ($2000 DDD) 3889 79,623 0.97 (0.94-1.01) 0.99 (0.96-1.03)
Cumulative dose (DDD)
1-399 4632 92,798 0.99 (0.96-1.03) 1.00 (0.96-1.03)
400-999 2317 47,961 0.96 (0.92-1.01) 0.97 (0.93-1.02)
1000-1999 2046 43,278 0.94 (0.90-0.99) 0.96 (0.91-1.01)
2000-2999 1235 25,624 0.95 (0.90-1.01) 0.97 (0.92-1.03)
3000-3999 796 16,561 0.96 (0.89-1.03) 0.97 (0.90-1.04)
$4000 1858 37,439 1.00 (0.95-1.05) 1.02 (0.97-1.07)
Squamous cell carcinoma
Nonuse 6331 130,503 1.0 (ref) 1.0 (ref)
Ever use 2298 41,959 1.14 (1.08-1.20) 1.00 (0.95-1.06)
High use ($2000 DDD) 735 13,034 1.18 (1.09-1.28) 1.00 (0.92-1.09)
Cumulative dose (DDD)
1-399 742 14,421 1.05 (0.97-1.14) 0.96 (0.88-1.04)
400-999 416 7545 1.15 (1.04-1.28) 1.05 (0.95-1.18)
1000-1999 405 6959 1.20 (1.08-1.34) 1.09 (0.98-1.22)
2000-2999 198 4203 0.98 (0.85-1.13) 0.87 (0.74-1.01)
3000-3999 164 2757 1.25 (1.06-1.47) 1.07 (0.91-1.27)
$4000 373 6074 1.28 (1.15-1.43) 1.08 (0.96-1.22)
ACE, Angiotensin-converting enzyme; CI, confidence interval; DDD, defined daily dose; NMSC, nonmelanoma skin cancer; OR, odds ratio; ref,
reference.
*Adjusted for age, sex, and calendar time by risk-set matching and the conditional analysis.
yFully adjusted model, that is, additionally adjusted for (1) use of topical retinoids, oral retinoids, tetracycline, macrolides, aminoquinolines,
amiodarone, and methoxypsoralene; (2) aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, or statins; (3) history of heavy alcohol
consumption, diabetes, chronic renal insufficiency, or chronic obstructive pulmonary disease; (4) Charlson comorbidity index (CCI) score (0,
low; 2, medium; or $3, high); and (5) highest achieved education (short, medium, long, or unknown).
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Supplemental Table V. Association between exposure to angiotensin II receptor antagonists and risk of
NMSC
Subgroup Cases Controls Adjusted OR (95% CI)* Adjusted OR (95% CI)y
Basal cell carcinoma
Nonuse 63,470 1,278,247 1.0 (ref) 1.0 (ref)
Ever use 8083 152,636 1.07 (1.04-1.10) 1.06 (1.03-1.09)
High use ($2000 DDD) 2659 48,517 1.11 (1.07-1.16) 1.08 (1.03-1.13)
Cumulative dose (DDD)
1-399 2086 39,981 1.06 (1.01-1.11) 1.05 (1.00-1.10)
400-999 1508 29,309 1.04 (0.99-1.10) 1.04 (0.98-1.10)
1000-1999 1830 34,829 1.06 (1.01-1.12) 1.05 (1.00-1.11)
2000-2999 1250 22,591 1.12 (1.05-1.18) 1.09 (1.03-1.17)
3000-3999 680 13,081 1.06 (0.98-1.15) 1.03 (0.95-1.12)
$4000 729 12,845 1.15 (1.07-1.24) 1.10 (1.02-1.19)
Squamous cell carcinoma
Nonuse 7353 149,367 1.0 (ref) 1.0 (ref)
Ever use 1276 23,095 1.13 (1.06-1.20) 0.93 (0.87-1.00)
High use ($2000 DDD) 457 7549 1.23 (1.12-1.36) 0.88 (0.79-0.99)
Cumulative dose (DDD)
1-399 327 5972 1.10 (0.98-1.24) 0.99 (0.88-1.12)
400-999 231 4336 1.08 (0.94-1.23) 0.95 (0.82-1.09)
1000-1999 261 5238 1.01 (0.89-1.15) 0.84 (0.73-0.97)
2000-2999 192 3542 1.10 (0.94-1.27) 0.82 (0.70-0.97)
3000-3999 136 1982 1.41 (1.18-1.68) 0.97 (0.81-1.18)
$4000 129 2025 1.30 (1.08-1.56) 0.86 (0.71-1.04)
CI, Confidence interval; DDD, defined daily dose; NMSC, nonmelanoma skin cancer; OR, odds ratio; ref, reference.
*Adjusted for age, sex, and calendar time by risk-set matching and the conditional analysis.
yFully adjusted model, that is, additionally adjusted for (1) use of topical retinoids, oral retinoids, tetracycline, macrolides, aminoquinolines,
amiodarone, and methoxypsoralene; (2) aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, or statins; (3) history of heavy alcohol
consumption, diabetes, chronic renal insufficiency, or chronic obstructive pulmonary disease; (4) Charlson comorbidity index score (0, low; 2,
medium; or $3, high); and (5) highest achieved education (short, medium, long, or unknown).
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Supplemental Table VI. Association between exposure to indapamide and risk of NMSC
Subgroup Cases Controls Adjusted OR (95% CI)* Adjusted OR (95% CI)y
Basal cell carcinoma
Nonuse 70,838 1,416,467 1.0 (ref) 1.0 (ref)
Ever use 715 14,416 0.99 (0.92-1.07) 0.99 (0.92-1.07)
High use ($2000 DDD) 44 911 0.97 (0.71-1.31) 0.97 (0.72-1.32)
Cumulative dose (DDD)
1-399 383 8150 0.94 (0.85-1.04) 0.94 (0.85-1.04)
400-999 191 3584 1.07 (0.92-1.24) 1.07 (0.92-1.24)
1000-1999 97 1771 1.10 (0.90-1.35) 1.11 (0.90-1.36)
2000-2999 23 516 0.88 (0.58-1.34) 0.88 (0.58-1.34)
3000-3999 15 240 1.25 (0.74-2.11) 1.28 (0.76-2.15)
$4000 6 155 0.79 (0.35-1.79) 0.81 (0.36-1.83)
Squamous cell carcinoma
Nonuse 8511 170,073 1.0 (ref) 1.0 (ref)
Ever use 118 2389 0.99 (0.82-1.19) 0.95 (0.79-1.15)
High use ($2000 DDD) 7 178 0.78 (0.37-1.67) 0.84 (0.39-1.79)
Cumulative dose (DDD)
1-399 67 1324 1.01 (0.79-1.29) 0.97 (0.75-1.24)
400-999 28 589 0.94 (0.65-1.38) 0.89 (0.61-1.31)
1000-1999 16 298 1.08 (0.65-1.78) 1.06 (0.64-1.77)
2000-2999 (n\5) 109 d d
3000-3999 (n\5) 49 d d
$4000 (n\5) 20 d d
CI, Confidence interval; DDD, defined daily dose; NMSC, nonmelanoma skin cancer; OR, odds ratio; ref, reference.
*Adjusted for age, sex, and calendar time by risk-set matching and the conditional analysis.
yFully adjusted model, that is, additionally adjusted for (1) use of topical retinoids, oral retinoids, tetracycline, macrolides, aminoquinolines,
amiodarone, and methoxypsoralene; (2) aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, or statins; (3) history of heavy alcohol
consumption, diabetes, chronic renal insufficiency, or chronic obstructive pulmonary disease; (4) Charlson comorbidity index score (0, low; 2,
medium; or $3, high); and (5) highest achieved education (short, medium, long, or unknown).
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Supplemental Table VII. Association between exposure to nifedipine and risk of NMSC
Subgroup Cases Controls Adjusted OR (95% CI)* Adjusted OR (95% CI)y
Basal cell carcinoma
Nonuse 70,563 1,412,975 1.0 (ref) 1.0 (ref)
Ever use 990 17,908 1.11 (1.04-1.18) 1.10 (1.03-1.17)
High use ($2000 DDD) 228 4206 1.08 (0.95-1.24) 1.08 (0.95-1.24)
Cumulative dose (DDD)
1-399 514 9216 1.12 (1.02-1.22) 1.10 (1.01-1.21)
400-999 117 2339 1.00 (0.83-1.20) 0.99 (0.82-1.20)
1000-1999 131 2147 1.23 (1.03-1.46) 1.23 (1.03-1.46)
2000-2999 61 1342 0.90 (0.70-1.17) 0.89 (0.69-1.15)
3000-3999 53 923 1.15 (0.88-1.52) 1.16 (0.88-1.53)
$4000 114 1941 1.17 (0.97-1.42) 1.18 (0.98-1.43)
Squamous cell carcinoma
Nonuse 8466 169,467 1.0 (ref) 1.0 (ref)
Ever use 163 2995 1.09 (0.93-1.28) 0.97 (0.82-1.14)
High use ($2000 DDD) 48 754 1.28 (0.95-1.71) 1.15 (0.85-1.54)
Cumulative dose (DDD)
1-399 71 1416 1.00 (0.79-1.27) 0.89 (0.70-1.14)
400-999 26 449 1.16 (0.78-1.72) 0.99 (0.66-1.48)
1000-1999 18 376 0.96 (0.60-1.54) 0.86 (0.54-1.39)
2000-2999 18 215 1.70 (1.05-2.75) 1.56 (0.96-2.54)
3000-3999 9 177 1.01 (0.52-1.98) 0.99 (0.50-1.94)
$4000 21 362 1.16 (0.75-1.80) 0.99 (0.63-1.54)
CI, Confidence interval; DDD, defined daily dose; NMSC, nonmelanoma skin cancer; OR, odds ratio; ref, reference.
*Adjusted for age, sex, and calendar time by risk-set matching and the conditional analysis.
yFully adjusted model, that is, additionally adjusted for (1) use of topical retinoids, oral retinoids, tetracycline, macrolides, aminoquinolines,
amiodarone, and methoxypsoralene; (2) aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, or statins; (3) history of heavy alcohol
consumption, diabetes, chronic renal insufficiency, or chronic obstructive pulmonary disease; (4) Charlson comorbidity index score (0: low; 2:
medium; or $3: high); and (5) highest achieved education (short, medium, long, or unknown).
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Supplemental Table VIII. Association between exposure to hydrochlorothiazide and risk of NMSC according
to the cumulative hydrochlorothiazide use, restricted to never-users of amiloride
Subgroup Cases Controls Adjusted OR (95% CI)* Adjusted OR (95% CI)y
Basal cell carcinoma
Nonuse 63,520 1,278,990 1.0 (ref) 1.0 (ref)
Ever use 5033 99,508 1.02 (0.99-1.05) 1.03 (1.00-1.06)
High use ($50,000 mg) 382 6457 1.19 (1.07-1.32) 1.21 (1.09-1.34)
Cumulative amount
1-9999 mg 2216 44,331 1.01 (0.97-1.06) 1.02 (0.97-1.06)
10,000-24,999 mg 1478 29,727 1.01 (0.96-1.07) 1.02 (0.96-1.07)
25,000-49,999 mg 957 18,993 1.01 (0.95-1.08) 1.02 (0.95-1.09)
50,000-74,999 mg 281 4792 1.18 (1.05-1.33) 1.20 (1.06-1.35)
75,000-99,999 mg 74 1173 1.27 (1.00-1.60) 1.29 (1.02-1.64)
100,000-149,999 mg 25 429 1.16 (0.77-1.73) 1.19 (0.79-1.78)
150,000-199,999 mg (n\5) 48 d d
$200,000 mg (n\5) 15 d d
Squamous cell carcinoma
Nonuse 6786 149,391 1.0 (ref) 1.0 (ref)
Ever use 754 14,629 1.14 (1.06-1.24) 1.13 (1.04-1.22)
High use 81 967 1.89 (1.50-2.39) 1.89 (1.50-2.39)
Cumulative amount
1-9999 mg 285 6334 1.00 (0.88-1.13) 0.98 (0.87-1.11)
10,000-24,999 mg 213 4459 1.06 (0.92-1.21) 1.05 (0.91-1.21)
25,000-49,999 mg 175 2869 1.36 (1.16-1.59) 1.35 (1.16-1.58)
50,000-74,999 mg 56 729 1.74 (1.32-2.29) 1.73 (1.31-2.28)
75,000-99,999 mg 12 181 1.58 (0.87-2.86) 1.60 (0.88-2.90)
100,000-149,999 mg 9 48 3.75 (1.81-7.77) 3.74 (1.80-7.76)
150,000-199,999 mg (n\5) 9 d d
$200,000 mg (n\5) (n\5) d d
CI, Confidence interval; NMSC, nonmelanoma skin cancer; OR, odds ratio; ref, reference.
*Adjusted for age, sex, and calendar time by risk-set matching and the conditional analysis.
yFully adjusted model, that is, additionally adjusted for (1) use of topical retinoids, oral retinoids, tetracycline, macrolides, aminoquinolines,
amiodarone, and methoxypsoralene; (2) aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, or statins; (3) history of heavy alcohol
consumption, diabetes, chronic renal insufficiency, or chronic obstructive pulmonary disease; (4) Charlson comorbidity index score (0: low; 2:
medium; or $3: high); and (5) highest achieved education (short, medium, long, or unknown).
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